Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma

Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma

Androgen Receptor (AR) signaling is a critical driver of hormone-dependent prostate cancer and has also been proposed to have biological activity in female hormone-dependent cancers, including type I endometrial carcinoma (EMC). In this study, we evaluated the preclinical efficacy of a third-generat...

Full description

Bibliographic Details
Main Authors:	Christopher S. Koivisto, Melodie Parrish, Santosh B. Bonala, Soo Ngoi, Adrian Torres, James Gallagher, Rebekah Sanchez-Hodge, Victor Zeinner, Georges J. Nahhas, Bei Liu, David E. Cohn, Floor J. Backes, Paul J. Goodfellow, Helen M. Chamberlin, Gustavo Leone
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	Neoplasia: An International Journal for Oncology Research
Subjects:	PTEN Androgen receptor antagonist Enzalutamide Endometrial carcinoma Preclinical drug evaluation Mouse model of endometrial cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558620301342

Similar Items

WWP2 and its association with PTEN in endometrial cancer
by: Aine E. Clements, et al.
Published: (2015-08-01)

Diagnostic and Prognostic Values of PTEN Expression in Functional and Pathological Endometrial Biopsies
by: Amal Nooredeen Allithy, et al.
Published: (2022-02-01)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
by: Timothy C. Wright, et al.
Published: (2021-07-01)

Immunohistochemical expression of PTEN (phosphatase and tension homolog) in endometrial carcinoma
by: Zena Adwal Ali, et al.
Published: (2023-04-01)

EVALUATION OF ALTERED PTEN EXPRESSION BY IHC AS A DIAGNOSTIC MARKER IN HYPERPLASTIC AND NEOPLASTIC ENDOMETRIUM OBSERVATIONAL DESCRIPTIVE STUDY.
by: Bodhisatwa Behera, et al.
Published: (2023-06-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01)

Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide
by: Xiaohong Xia, et al.
Published: (2019-05-01)

Androgen Receptor Blockade Using Enzalutamide Suppresses Long Non-Coding RNA ARLNC1 in Prostate Cancer Cells
by: Günel Huseynova, et al.
Published: (2022-12-01)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
by: Ralph E. White, et al.
Published: (2023-06-01)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
by: Alexandra Vander Ark, et al.
Published: (2018-05-01)

Assessment of endometrial carcinoma on biopsy as a predictor of final surgical pathology: Are we doing it right? A completed audit cycle and recommendations
by: Aneeta Jassar, et al.
Published: (2023-07-01)

Increased PTEN gene expression in patients with endometrial carcinoma from areas of high risk depleted uranium exposure
by: Alaa Salah Jumaah, et al.
Published: (2019-10-01)

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
by: Peng-Fei Zhang, et al.
Published: (2021-02-01)

Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study
by: Takashi Kawahara, et al.
Published: (2025-01-01)

Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
by: Onur Baser, et al.
Published: (2024-04-01)

TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
by: Louie Semaan, et al.
Published: (2019-10-01)

Enzalutamide Induces Apoptotic Insults to Human Drug-Resistant and -Sensitive Glioblastoma Cells via an Intrinsic Bax-Mitochondrion-Cytochrome C Caspase Cascade Activation Pathway
by: Chia-Yu Chang, et al.
Published: (2022-10-01)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
by: Xiangyun You, et al.
Published: (2023-04-01)

Possibilities of treatment of patients with castrationrefractory prostate cancer using enzalutamide
by: B. Ya. Alekseyev, et al.
Published: (2019-12-01)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
by: Giorgia Gurioli, et al.
Published: (2020-09-01)

Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis
by: Ahmet Dirican, et al.
Published: (2022-11-01)

Genetic Profiling of Glucocorticoid (NR3C1) and Mineralocorticoid (NR3C2) Receptor Polymorphisms before Starting Therapy with Androgen Receptor Inhibitors: A Study of a Patient Who Developed Toxic Myocarditis after Enzalutamide Treatment
by: Manuel Morales, et al.
Published: (2022-05-01)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
by: Kouji Izumi, et al.
Published: (2022-07-01)

MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway
by: Shengfeng Zheng, et al.
Published: (2024-10-01)

Enzalutamide and antiretroviral drugs: a challenge for clinicians
by: G. Gardini, et al.
Published: (2021-09-01)

Changing the Timing of Enzalutamide Intake from Morning to before Sleep at Night Overcame Enzalutamide-Induced Dysgeusia
by: Takashi Kawahara, et al.
Published: (2019-08-01)

Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer
by: Marcus Moses, MS, et al.
Published: (2020-01-01)

High androgen level during controlled ovarian stimulation cycle impairs endometrial receptivity in PCOS patients
by: Si-Yi Wei, et al.
Published: (2024-10-01)

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
by: Zhe Zhu, et al.
Published: (2024-11-01)

New Marine Fungal Deoxy-14,15-Dehydroisoaustamide Resensitizes Prostate Cancer Cells to Enzalutamide
by: Sergey A. Dyshlovoy, et al.
Published: (2023-01-01)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
by: Zhe Hong, et al.
Published: (2021-07-01)

COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial
by: Karin Welén, et al.
Published: (2021-03-01)

Sequential Androgen Receptor Pathway Inhibitor in Prostate Cancer: Piling-Up The Benefits or a Case for Cross-Resistance?
by: Bertrand Tombal
Published: (2014-11-01)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
by: Namrata Khurana, et al.
Published: (2020-01-01)

Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
by: Xiang Gao, et al.
Published: (2024-08-01)

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer
by: Rosanne CV. Van der Roest, et al.
Published: (2016-07-01)

The characteristics of expression proliferation markers in endometrial hyperplasia
by: M R Dumanovskaya, et al.
Published: (2013-04-01)

Cordycepin alleviates endometrial hyperplasia in rats via alteration of PTEN/PI3K/Akt axis
by: Abdulmohsin J. Alamoudi, et al.
Published: (2024-08-01)

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer
by: Yan Li, et al.
Published: (2022-11-01)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
by: Nair Lopes, et al.
Published: (2021-08-01)